Exploring Retatrutide's Potential Benefits in GLP-1 Research | Retatrutide News

Retatrutide, a GLP-1 agonist from Eli Lilly, is being explored for potential metabolic benefits. The article highlights growing interest but lacks speci...
Market News · October 10, 2026